Last reviewed · How we verify
Allopurinol Pill
At a glance
| Generic name | Allopurinol Pill |
|---|---|
| Also known as | Zyloprim |
| Sponsor | Instituto Nacional de Cardiologia Ignacio Chavez |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Allo HSCT Using RIC and PTCy for Hematological Diseases (PHASE2)
- Effect of Allopurinol on Markers of Mineral and Bone Metabolism (NA)
- Allo HSCT Using RIC for Hematological Diseases (PHASE2)
- Allopurinol in Acute Coronary Syndrome (PHASE4)
- Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms (PHASE2, PHASE3)
- The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics (PHASE4)
- Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms (PHASE3)
- Xanthine Oxidase Inhibition in Renal Transplant Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allopurinol Pill CI brief — competitive landscape report
- Allopurinol Pill updates RSS · CI watch RSS
- Instituto Nacional de Cardiologia Ignacio Chavez portfolio CI